TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06121843: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 187 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$6,754,440

Rescue Site Savings

+$4,461,072

Unlock Full NCT06121843 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06121843 Rescue Dossier →